The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public-and private-sector organizations in their efforts to improve the quality of health care in the United States. The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments.
 Tables  Table 1. 
Introduction
Comparative effectiveness or patient-centered outcomes research (CER/PCOR) has been defined by the Federal Coordinating Council for CER as "the conduct and synthesis of research comparing the benefits and harms of different interventions and strategies to prevent, diagnose, treat and monitor health conditions in 'real world' settings." 1 The purpose of CER/PCOR is "to improve health outcomes by developing and disseminating evidence-based information to patients, clinicians, and other decisionmakers, responding to their expressed needs, about which interventions are most effective for which patients under specific circumstances."
1 The interventions compared may include medications, procedures, medical and assistive devices and technologies, diagnostic tests, behavioral changes, and delivery system strategies.
1 CER/PCOR designs may include clinical trials, observational studies, secondary analyses of databases, systematic reviews with or without meta-analyses, and cost-effectiveness analyses. CER/PCOR is conducted within a framework that encompasses a variety of activities as illustrated in Figure 1 . All of these activities are ultimately aimed at improving health care. The Agency for Healthcare Research and Quality (AHRQ) is the lead Federal agency charged with improving the quality, safety, efficiency, and effectiveness of health care for all Americans. As 1 of 12 agencies within the Department of Health and Human Services, AHRQ supports health services research to improve the quality of health care and promote evidencebased decisionmaking; AHRQ supports a variety of CER/PCOR activities through its Effective Health Care (EHC) Program. 2 The EHC Program funds individual researchers, research centers, and academic organizations that work with AHRQ to produce effectiveness and comparative effectiveness research for clinicians, consumers, and policymakers. To contribute to its agenda for CER/PCOR activities related to mental health, AHRQ contracted the RTI InternationalUniversity of North Carolina (RTI-UNC) Evidence-based Practice Center (EPC) and the Scientific Resource Center Stakeholder Engagement Team to engage a broad and representative group of stakeholders to discuss issues related to serious mental illness (SMI) in a series of three meetings (Issues Exploration Forum [IEF] ), as detailed in the methods section.
The results of three large comparative effectiveness trials have been sobering, and arguably have highlighted the limitations of our current ability to help many patients afflicted with schizophrenia, bipolar disorder, and depression. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study reported that an older typical antipsychotic medication was as effective as the newer, more publicized atypical antipsychotics when used as a first-line treatment. In addition, nonadherence to medication was the norm, not the exception, with almost 75 percent of patients not using their medication after 18 months of treatment. 3 The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) trial reported that about 40 percent of bipolar patients do not recover from a manic episode. 4 In addition, for those who do recover, the relapse rates for either a subsequent depressive or manic episode were about 50 percent over the following 2 years. In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, after 13 weeks of treatment with a selective serotonin reuptake inhibitor only a third of patients met remission criteria. 5 Furthermore, after another 39 weeks of treatment only another third of the initial cohort remitted, leaving a full third of patients symptomatic. 6 Reports from the Schizophrenia Patient Outcomes Research Team (PORT) underscore the point that effective treatments are available, but implementation and uptake are suboptimal. 7 More than 30 percent of the U.S. population suffers from a mental illness each year. 8 Of this group, 22 percent are classified as serious, 37 percent as moderate, and 40 percent as mild. 9 In sum, about 17.8 million people (5.8 percent of the U.S. population) live with SMI in any given year, resulting in significant economic and societal consequences. Several working definitions of SMI, severe mental illness, or severe and persistent mental illness have been used. [10] [11] [12] [13] [14] [15] [16] [17] [18] For this IEF's purposes, we used the following criteria to define adults with SMI: 18 people who (1) are ages 18 or older; (2) currently have, or at any time during the past year had, a diagnosable mental, behavioral, or emotional disorder of sufficient duration to meet diagnostic criteria specified within the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) or the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) equivalent (and subsequent revisions); and (3) have functional impairment that substantially interferes with or limits one or more major life activities. Major life activities (in part 3 of the definition) include basic daily living skills (e.g., eating, maintaining personal hygiene); instrumental living skills (e.g., managing money, negotiating transportation, taking medication as prescribed); and functioning in social, family, and vocational or educational contexts. 19 American adults living with SMI die about 25 years earlier than other Americans, largely owing to treatable medical conditions. 20 In fact, many people with SMI do not seek any health care. 21 On average, those with SMI report being totally unable to carry out their normal daily activities for 88 days per year compared with 4.7 and 1.9 days, respectively, for those classified as having a moderate or mild mental illness. 9 SMI is the second-leading cause of disability in the United States for ages 15 to 44 22 and accounts for between 5,000 and 10,000 disability-adjusted life years lost worldwide per year per 1 million population.
In 2002, SMI was estimated to cost more than $100 billion in health care expenditures alone. 23 Loss of earnings as a result of SMI was estimated to be about $193 billion, and disability benefits cost an additional $24.3 billion, resulting in a total of more than $317 billion spent on SMI in 2002. 23 SMI represents the largest diagnostic category for people receiving Supplemental Security Income (SSI) and Social Security Disability Insurance (SSDI) payments from the Federal Government. Table 1 provides data on the burden of disease associated with SMI and mood and psychotic disorders. DALY= disability-adjusted life year. *"12-month prevalence" refers to the proportion of study participants who identified symptoms occurring in the 12 months preceding the study interview that could be categorized as a mental health disorder. **"Lifetime prevalence" was estimated based on the proportion of respondents who had ever had the mental health disorder at the time of the interview. Mood disorders are broadly recognized as either depressive disorders, including major depressive disorder (MDD) or bipolar disorder (BD). MDD affects approximately 14.8 million American adults, or 6.8% of the U.S. population ages 18 and older in a given year. 31 Of the 9.7% of the population diagnosed with mood disorders in a 12-month period, 45% are classified as serious. 9 About 30% of MDDs, 50% of dysthymias, and 83% of BDs are serious.
†
Receiving any treatment in the 12 months before interview, by a psychiatrist, general practitioner, family physician, any other physician, social worker, counselor, any other mental health professional, religious or spiritual advisor, or any other healer.
We limited the scope of the IEF to adults with SMI who have psychotic or mood disorders because these disorders account for the majority of SMI and because our time and resources were limited. We did not include alcohol-and substance-related disorders, developmental disorders, anxiety disorders, or personality disorders, unless they co-occurred with a psychotic or mood disorder. Figure 2 illustrates the focus of the IEF and the relationship among SMI, mood disorders, and psychotic disorders.
The overarching purpose of this Issues Exploration Forum was to contribute to the establishment of priorities to guide CER/PCOR activities in mental health by engaging a diverse group of stakeholders. We aimed to focus on an area of mental health with significant unmet need despite available interventions and an area in which conducting CER/PCOR is likely to have an impact on reducing variation and uncertainty in clinical practice and outcomes, reducing methodological and conceptual uncertainty, and reducing disease burden. Additional objectives were to identify knowledge gaps in the area of SMI and to generate and prioritize topics for future CER/PCOR, including topics for evidence synthesis (i.e., systematic reviews, comparative effectiveness reviews). SMI: 8.3% (12-month prevalence) Mood disorders: 9.7% (12-month prevalence) Psychotic disorders including schizophrenia: 1.5% (lifetime prevalence)
Mood Disorders
Psychotic Disorders SMI Sources: National Comorbidity Survey. 8 Epstein J, et al.
32

Methods
Stakeholder Engagement
We sought a broad array of stakeholder opinions to balance perspective, minimize bias, and ensure that diverse perspectives were reflected. We made sure to include stakeholders who represented important subpopulations, such as those with ethnic, cultural, socioeconomic, or racial disparities associated with SMI.
Stakeholders were identified by input from the RTI-UNC EPC, AHRQ, and the Scientific Resource Center, and they represented a cross-section of patients, family members, consumers, advocates, practicing clinicians, professional societies, policymakers, public and private payers, Federal agencies, researchers, and methodologists. We used standard recruitment practices to secure participation. Stakeholders were contacted via telephone followed by a written e-mail invitation that included a brief overview of the IEF. Those stakeholders who declined to participate were asked to provide a substitute from their organization or who represented their perspective if there was no organizational affiliation, to ensure a broad and balanced representation. If a substitute was unavailable, we used a substitution list to find a comparable replacement.
Preparation. Confirmed participants were offered an orientation on AHRQ and the EHC Program. Orientation sessions reviewed the history, goals, and objectives of the EHC Program, discussed AHRQ research processes most relevant to the forum (topic generation, nomination, and selection), discussed the goals and objectives of the forum, and reviewed expected roles of participants in the forum. A brief outline of all EHC Program public involvement opportunities was also included. Several dates and times were offered over the course of 3 weeks before the forum began. The sessions were conducted using a Web-hosted PowerPoint presentation. Participants received a PDF version of the presentation, the Federal Coordinating Council's definition of CER, a brief definition of a PICOTS (Patients, Interventions, Comparators, Outcomes, Treatments, Settings) framework for research synthesis questions, and a draft version of the EHC Program selection criteria for new research.
Prior to the IEF phone and in-person meetings, participants received materials by e-mail. Materials included documents describing the background and objectives of the forum, the definition of CER and related terminology, the definition of SMI and the scope of the forum, the organizing framework, a process summary for determining the focus area of the forum, draft selection criteria for new research, examples of mental health CER/PCOR topics, a summary of the burden of SMI, past CER tables, a summary of the populated organizing framework, a populated framework, and an environmental scan bibliography.
Topic generation. To generate topics, three meetings were held; the first and third meetings were held via conference call, using Web-hosted presentations, whereas the second was an allday, in-person meeting at the AHRQ offices in Rockville, Maryland. A professional facilitator was used to aid the discussion during all meetings.
The objectives of the first meeting were to introduce the goals and format, and to gather initial feedback related to stakeholder areas of interest. At the meeting, participants received a brief summary of the meeting materials described above, and then discussed them by providing feedback in the areas of greatest interest related to research on SMI.
We invited participants to continue the discussion and submit research ideas and broader ideas using an online forum hosted by AHRQ. They received login information and instructions for posting to the online forum. Potential research topics were accepted for 5 days following the meeting. We also accepted topics by e-mail and phone and posted them on behalf of participants to the online forum. The suggestions made by participants readily grouped into three main themes: (1) patient-centered care-improving outcomes that matter to patients, (2) conceptual frameworks for research, and (3) reduction of disparities for subpopulations.
The objectives of the in-person meeting (second meeting) were to discuss broad issues in the area, identify gaps, and generate and prioritize research topics that can address these issues and gaps. Participants received meeting materials via e-mail in advance and binders with hard copies of related materials at the meeting.
Participants were pre-assigned to one of three workgroups corresponding to the themes emerging from the potential research topics that participants suggested during and following the first meeting. Group assignments were made to balance perspectives in each of the workgroups. Each workgroup reviewed the list of previously submitted topics in its theme and generated additional topic ideas through facilitated group discussion. The workgroups presented brief overviews of their discussions and reviewed the additional topic ideas generated. All topic ideas were recorded and displayed in the meeting room. Following a facilitated discussion of the full group, participants offered amendments using a rolling feedback process. Suggested changes were written on self-adhesive notes and placed next to the appropriate topic idea.
Topic prioritization. After final review and discussion, a nominal group process was used to identify initial priorities. Stakeholders used stickers to indicate which topics should be given highest priority for research. Participants were allotted 20 stickers, and allowed to place between 1 and 5 stickers on any one topic idea. We tallied the stickers and reported the results of the initial prioritization to the group. All topic ideas were captured in meeting notes for further analysis.
Organization of prioritized topics into common themes. Following the in-person meeting, we sorted and organized the topics by theme across the meeting workgroups. Topics were qualitatively assessed by teams of investigators and compared both within and across initial groupings. Special attention was given to topics that were closely related. Topics were then exchanged with other teams and reanalyzed. We organized the topics from the second meeting into 21 common topic themes. Two documents were created to organize results and display the topics according to priority, based on the number of stickers received at the in-person meeting.
The objectives of the final meeting were to review the prioritized topic themes, gather feedback on the process used to organize the prioritized topics, and get a preliminary sense of which topics are appropriate for evidence synthesis, evidence generation, and other research activities and products. Before the meeting, participants received the list of prioritized topics and were given a chance to give feedback and to comment on the list.
Results
Appendix A provides a list of IEF stakeholder attendees. Nineteen stakeholders attended the first, Web-based IEF meeting. The initial topics given to the stakeholders for consideration at the start of the IEF and resulting discussion among stakeholders via the AHRQ Extranet Web site yielded 59 topics and 23 ideas. These 82 combined topics and ideas formed the basis for the three small group discussions during the breakout session of the in-person meeting on July 30, 2010 .
The second IEF meeting included 33 stakeholders. The 82 topics and ideas generated prior to the in-person meeting were fairly equally divided among the three small groups with slightly more topics and ideas falling within the realm of patient-centered care. The small group sessions generated approximately 80 additional topics and ideas; the majority again fell into the patientcentered care group (~42 percent), followed by the reducing disparities for subpopulations (~33 percent) and conceptual framework for research (~25 percent) groups. After initial prioritization, nearly half had received at least 1 sticker from stakeholders, with 15 topics/ideas receiving 12 or more stickers. Following the in-person meeting, the RTI-UNC EPC staff combined similar topics into unique groups. After eliminating duplicate topics/ideas, the result was roughly 140 topics subsumed within 21 main themes (Table 2 ) prioritized by total number of stickers received during the second meeting.
During the final IEF meeting, the 13 stakeholders in attendance identified 11 of the 21 prioritized themes as being appropriate for evidence synthesis. Stakeholders were also provided an opportunity to help develop the the effectiveness reviews into research no stakeholders expressed interest in assis Appendix B provides a brief descriptio them, as well as those deemed appropr 4. Development of CER/PCOR methodology. This thread includes topics related to the need to develop methodology for comparative effectiveness research (CER/PCOR) for mental health, including the need for (a) methods to adjust for confounding during followup; (b) more work using performance-based measures for increased validity and reliability; (c) exploring and expanding the use of new and different study designs and data analysis strategies (e.g., illness trajectories, propensity scores, time series); (d) longer-term studies and research conduct and design strategies aiming to optimize long-term followup, while avoiding attrition bias and avoiding confounding; (e) consumer and patient involvement; (f) a taxonomy to define and describe psychosocial and psychotherapeutic interventions; and (g) integration of biological and psychosocial research.
5. Identify disparities and reasons for disparities and reevaluate the framework for researching disparities.* This thread includes topics related to the need to clearly document disparities (in both public and private settings) and identify the reasons for disparities. Considerations for further research include (but are not limited to) barriers and access issues, clinical reasons, systems issues, institutional racism, and lack of services to people with limited English-language skills. In addition, this thread includes topics related to the need to reevaluate the framework for researching disparities. For example, needs were identified for more research focused on specific racial and ethnic communities, outcomes of greatest interest to specific populations or communities, and addressing the overall lack of inclusion as participants in research. 7. Strategies to personalize/individualize treatment. This thread includes comparisons of strategies to personalize/individualize psychotropic medication treatment for people with SMI. This includes identifying variations in patient response and predictors of response/tolerance that could inform the selection of treatments for specific groups of patients (e.g., by age, race, ethnicity, culture, and common comorbidities). This may include using biomarkers/pharmacogenomics, studying the relationship of race and ethnicity with intervention and outcome, using large databases to assess individualized treatments, targeting specific interventions to individuals' goals and wishes, or integrating decision analysis into a comparative effectiveness trial to develop approaches to improving outcomes through individualizing care. 21. Strategies to reduce stigma, prejudice, and discrimination.* This includes comparisons of strategies to reduce stigma, prejudice, and discrimination against people with SMI and to encourage their social inclusion.
[PC] †A detailed list of all topics related to the 21 themes is provided in Appendix B. Number in bold in parentheses after each item indicates the number of times a stakeholder expressed a preference for that topic. * This topic was determined by the stakeholder to be appropriate for evidence synthesis. R -Topics for this theme came from the conceptual framework for research workgroup. PC -Topics for this theme came from the patient-centered care workgroup. D -Topics for this theme came from the reducing disparities workgroup.
Discussion Need To Fundamentally Change Our Approach to Clinical Research for Serious Mental Illness
The topics prioritized by stakeholders deviated somewhat from our expectations. We had anticipated that stakeholders would focus mostly on head-to-head comparisons of evidencebased treatments or interventions, or on studies to fill gaps in the literature. Instead, three of the top four priorities focused on how research was conducted, namely (1) developing consensus measurement and outcomes definitions; (2) improving infrastructure for research, longitudinal studies, new data sets, and new investigators; and (3) developing CER/PCOR methodology. These findings highlight a feeling expressed by many stakeholders: failure to fundamentally change the way research on SMI is conducted will significantly prevent the field from moving forward.
Briefly examining landmark studies conducted over the last decade may explain how and why this occurred. First, the CATIE, STEP-BD, and STAR*D trials reported very sobering results, clearly demonstrating that our treatments are not as effective as we might have hoped.
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Most patients with a psychotic disorder and many patients with a mood disorder suffer significant morbidity. Although those studies were originally designed in the late 1990s, arguably no new pharmacological or psychosocial treatments have become available since then that could be considered "game changers." Despite the pessimism, PORT 7 reports highlight a number of both types of treatments that are clearly superior to placebo, though almost all available treatment algorithms typically characterize these independently (i.e., separate algorithms for each). Further, the rates at which patients' treatment conformed to PORT recommendations were modest at best (generally below 50 percent), and rates were higher for pharmacological than for psychosocial treatments, and in rural areas than in urban areas. 7 As the results of large comparative effectiveness trials like CATIE, STEP-BD, and STAR*D have become available, there is a growing recognition that although most SMI is a chronic lifetime disorder, most current research evaluates outcomes after an intervention over a much shorter time frame. [33] [34] [35] Long-term studies reporting the most important outcomes (e.g., disability, functional ability, and quality of life) are lacking for people with SMI despite the chronic and disabling nature of these conditions. How does one rationally place treatments with 6-week to, at most, 1-to 2-year outcomes, typical in previous pharmacologic and psychosocial intervention trials, in the framework of an illness that will last 30, 40, or 50 years? How would one actually assess outcomes in a lifelong illness? Many individuals with SMI are initially diagnosed in their 20s. Thus, they live the majority of their lives with considerable disabilities in comparison with people who do not have the illness. Given this, our current model for treatment may need to shift to one that is more consistent with a chronic illness model of care. This shift has occurred with certain medical illnesses with some benefits reported.
36 Interestingly, stakeholders emphasized the value of the therapeutic relationship in the treatment of chronic mental illness and the need for further CER/PCOR to clearly consider or further evaluate the role of the therapeutic relationship. A good therapeutic relationship is critical for many aspects of successful treatment, including engagement in treatment, and is very consistent with a chronic illness model of care.
Perhaps the most significant change in the conceptualization of severe mental illness over the past 20 years has been the emergence of the Recovery Model. 37 The main impetus for this change came from consumers themselves, who felt that the classic medical model of disease led to unnecessary stigmatization and the perception of hopelessness. Although there is strong evidence of continuing morbidity for most patients with SMI, there is also strong evidence that the vast majority of patients do not progressively deteriorate over time, and that as many as 50 percent to 70 percent of people with schizophrenia can go on to work and have "productive" lives. There are 10 core components of the Recovery Model with an emphasis on choice, empowerment, and hope. The model focuses on people's strengths, not their symptoms. Recovery from a major mental illness is seen similarly to recovery from a severe myocardial infarction. Individuals may have a damaged myocardium, but they are people with other aspects to their lives and are not wholly characterized with labels as cardiac patients. Currently, there is very limited research on this model.
On the surface there seems to be a possible disconnect between talking about "recovery" on one hand and suggesting on the other hand that this is a chronic lifetime illness that needs to be studied long term. However, it may well be that the stakeholders (who included two consumers) were also getting at the different phases of chronic mental illness. Although most of the research has been on the more acute phase of the illness, most individuals spend the vast majority of their illness in the nonacute phase. A recent published report suggested that schizophrenia could be conceptualized as a neurodevelopmental disorder with a later onset psychotic portion. 38 More research on what factors promote recovery over the long term would seem to be consistent with both models.
Comparisons of Evidence-Based Interventions and Addressing Knowledge Gaps
Although the top priorities centered on the need to revamp the research framework, stakeholders also identified a number of priority interventions for comparative effectiveness research. Service delivery, treatment settings, and structuring the delivery of care were identified as priority interventions for CER/PCOR (priority 3), which is not surprising and seems to follow a trend. Close to half of all mental health topics in the Institute of Medicine report Initial National Priorities for Comparative Effectiveness Research are related to systems and delivery of care. 39 The Federal Coordinating Council for CER also noted that CER to date "has been disproportionately focused on pharmacologic treatments rather than the full spectrum of intervention types" and further concluded that "the emphasis on pharmacologic treatments has meant fewer resources for other interventions, including behavioral, procedures, prevention, and delivery system interventions that can have major impacts on health outcomes." 1 Comparisons of treatment approaches to avoid early morbidity and mortality were highlighted as a priority (priority 8). A point of emphasis at the in-person meeting was that people with SMI die 25 years earlier 20 on average and that something must be done to improve this early mortality. Comparisons of strategies to personalize and individualize treatment and to increase adherence to evidence-based guidelines and treatment regimens, including the role of EMRs and decision support, were identified as other priority interventions for CER/PCOR.
Priority Populations
Stakeholders identified two priority populations as targets for CER/PCOR: people with SMI and comorbid medical illness or substance abuse and people with SMI involved in the criminal justice system (priorities 8, 12, and 13) . A need for research focused on specific ethnic and racial communities and a need to identify disparities and the reasons for disparities related to access, systems issues, institutional racism, and lack of services to people with limited English-language skills (priority 5) highlight additional possible targets for CER/PCOR.
Using Stakeholder Engagement to Identify Priorities for Research
The process used to establish research priorities during the IEF was considered successful. Engagement of a broad and representative group of stakeholders in a transparent process driven by the participants and aided by a neutral facilitator resulted in the identification of knowledge gaps, broad conceptual and methodological issues related to research, and priority areas for CER/PCOR. Stakeholders with a variety of decisional needs identified their priorities and preferences, clearly indicating a need to change the way research on SMI is conducted, including a need for improved methodologies to result in better evidence, practice, and patient outcomes. Using a process similar to this IEF can provide a novel way to generate state-of-the-field thinking, allowing the overarching issues in a field to emerge. Even more robust results could likely be obtained by addressing identified process limitations. Resource constraints limited the number and scope of participants. Similarly, although the most productive part of the process was the in-person meeting (meeting 2), resources limited face-to-face interaction to a single meeting. We experienced attrition in participation at meeting 3 following the in-person meeting and a request for more face-to-face interaction from some stakeholders.
Many of the organizations that participated in the IEF were not initially familiar with the EHC Program and CER. To participate fully, they required the context provided at the optional orientation sessions and a basic understanding of how CER/PCOR might be beneficial to them. This was a critical step, especially for nonclinician/researcher participants. At the end of the process, the majority of participants indicated a basic understanding of CER/PCOR and the EHC Program as well as a willingness to continue to participate in similar processes. To that end, investigators and individual stakeholders are currently working together to advance priority topics for consideration in the EHC Program.
It was necessary to identify, define, and communicate to the stakeholders the variables that might have affected the outcome of the process and the stakeholder experience. These variables included the goal of the IEF, expected outputs, how stakeholders were involved and represented, how the process was facilitated, and what was driving the process.
Having a dedicated and neutral focus enhanced the likelihood of a successful process and outcome. It was important to have a topic-neutral "bridge" between stakeholders with different perspectives in the research process and to facilitate communication between stakeholders and researchers or program staff. Having a facilitator to act in a neutral capacity focused on process allowed us to establish common ground among myriad perspectives, communicate stakeholder interests in ways understandable by a research-savvy audience, and translate basic evidencesynthesis needs so that stakeholders could communicate their ideas in ways that could be acted upon by the EHC Program.
As stakeholder and public involvement in the research enterprise becomes increasingly expected, it will be important to invest in the processes and tools that enable successful engagement. 19 .
Center The way that documentation requirements (which are driven by a multiplicity of payers and regulatory agents) drive assessment, treatment, and the nature of the relationship between the clinician and the individual receiving care has not been well studied, either in terms of benefits in influencing quality or in terms of the "unintended consequences" of specific requirements that decreased quality. Attention to documentation and specific research to develop effective and efficient approaches is particularly important to enhancing interoperability to developing electronic health records that adequately meet the needs of professionals and patients. • R NT8. Make treatment settings into experiments for studies. Explore which factors built into the structure of current health care contribute (or not) to patient adherence, especially for SMI-also consider differences in sectors (public or private), and develop needed criteria of evaluation success. (25) B-2 i. SH Note: Building an infrastructure for long-term research is critical, but it is expensive. Consider partnering with other agencies (e.g., National Institutes of Health, Department of Housing and Urban Development, Department of Justice, Department of Defense, and Department of Energy) to, for example, create a "superfund" to support long-term outcomes research.
• D 33. Small area variations in overall well-being. (4) i. Gallup research. ii. Pharma only-no psychosocial support. iii. Scalability of small area intervention.
• R NT11. Majority of people with SMI not getting care at all (never even touching the mental health care system), or not over time. This is not trivial. Must detect and care for mental health patients in general medical settings. and formal medical decisionmaking analysis. The latter requires that data from existing trials be reported in terms of proportions rather than change in symptoms scores (e.g., x percent of those given treatment y have at least a 50 percent response in symptoms, a percentage of those treated with y develop side effect z). This information would be more clinically useful than knowing that the treatment leads to a statistically significant (but not clinically significant) effect.
• R NT15. "Organizations of system" mirrors organization of research. (0) i. SH Note: The infrastructure daily registry development should involve the National Institute of Mental Health to have standardization and linkage to emerging research around enhancing the registry elements and for generalizability of research findings to natural solutions. ii. SH Note: Framework-amend the measure development-we desperately need this for behavioral health. iii. R NT16. Careful measurements over time. • R NT7. Need to develop methodology for CER/PCOR for mental health. Need methods to adjust for confounding post-baseline (i.e., during followup)-using global measures of functioning (e.g., more work is needed to use performance-based measures in mental health research for increased validity and reliability for mental health). (20) • R NT3. Develop a mental health study design that includes how to control for nonspecific affects, outcomes relevant for real-life settings, as current a particular limitation for mental health is that short-term clinical trials do not translate well into long-term trials. (7) i. SH Note: Research on psychosocial and psychotherapeutic interventions requires a guiding taxonomy/framework to define and describe approaches. For instance, labeling/grouping of treatments varies considerably (depending on investigators and available data) across systematic reviews and randomized controlled trials. For instance, mindfulness-based cognitive therapy, cognitive behavioral therapy (CBT) vs. cognitive vs. problem-solving therapy, etc., for major depressive disorder. Should these be evaluated as distinct treatments or are they better viewed as minor variations (or replications) within a broader CBT model? The importance of such a taxonomy for grouping analysis and comparison of treatments cannot be emphasized enough! What are B-4
"common"/"necessary" components to distinguish CBT, NS interpersonal psychotherapy vs. psychodynamic psychotherapy? • D 36. Research/reevaluation of priorities in biological vs. psychosocial research.
There needs to be better integration of these-need to consider the whole person. For the most part we only study the impact of treatments over short periods. (0) • R I-2. In order to determine the benefits of early interventions in SMI in terms of avoided disability and distress, it is imperative that investigations be funded and conducted over long periods of followup. (0) • R I-7. Long-term study designs need to consider potential confounding factors that may "wash out" the effect of the intervention (e.g., shifts in public mental health services, managed care penetration, hospital lengths of stay). These factors can be taken into consideration but require that a sizeable sample be present at the start. (0) • R I-9. Due to predictable attrition and various potential confounders, sizeable samples are needed for long-term studies to adequately maintain sufficient power for longitudinal conclusions to be drawn. • R I-16. There is a need for more research focused on specific racial and ethnic communities and any research focus should include outcomes specific to these populations. Must address the overall lack of evidence-based practice inclusion of racial and ethnic communities as participants in research. various outcomes, including whether the individual and involved family felt that the factors prompting the admission were adequately addressed, whether the individual and involved family felt that the stay was sufficient to address safety and dangerousness concerns, and whether differences in length of stay influence other variables (e.g., satisfaction with care, adherence, insight into illness) in SMI patients with similar diagnoses and disease severity. In this comparison, consider whether factors such as housing stability or social support network confound the relationship between length of stay and readmission rates. (7) i. SH Note: Include readmissions because mental health diagnosis & mental health impact on physical health. ii. SH Note: As part of examining the role of inpatient hospitalization, examine:
(1) the role of step-down transition in community-based settings and (2) the role of alternatives to inpatient care (caring (?) residential, home-based, intensive outpatient). 
